We use
genetic insights to develop novel
therapeutics for cancer
23ME-00610, a first-in-class investigational antibody targeting the immune checkpoint CD200R1
23andMe Therapeutics, a division of 23andMe, Inc., is a biotech company aiming to help people access, understand and benefit from the human genome. 23andMe Therapeutics has adopted a novel approach to drug discovery, guided by genetic and health data from consenting 23andMe participants.
23ME-00610 is a first-in-class investigational antibody drug designed to restore the ability of the body's immune cells to kill cancer cells by disrupting the immune checkpoint CD200R1.
Learn more about 23ME-00610
See how 23andMe Therapeutics developed this potential cancer treatment and find out how it works.
The potential of 23ME-00610
Our drug discovery approach helps us develop potential cancer treatments using genetic data.
Developed in-house by 23andMe Therapeutics scientists
Treatments validated by genetic data are 2 to 3 times more likely to become approved drugs.† Footnote
Informed by data from millions of people
About 80% of our millions of customers consent to participate in research, allowing us to obtain insights into how genetics impact disease.
Targeting CD200R1
CD200R1 is an immune checkpoint receptor that interacts with CD200 in tumors.
More information about the Phase 1/2a clinical trial
A clinical trial studying the safety of 23ME-00610 is currently underway in select patients with advanced, solid malignancies.
dagger Nelson, M.R., et al., The support of human genetic evidence for approved drug indications. Nat Genet, 2015. 47(8): p. 856-60; Ochoa, D., et al., Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. Nat Rev Drug Discov, 2022. 21(8): p. 551.
Be one of the first to get updates
Connect with us to receive information about the 23ME-00610 clinical trial and more.